Previous 10 |
home / stock / cmvlf / cmvlf news
Introduction Since my last article on Allogene Therapeutics ( ALLO ) about 5 months ago, its share price has fallen by around 30%, largely in part due to the stock market crash driven by the COVID-19 global pandemic . Despite the progress in clinical development, strong management tea...
Introduction Sangamo Therapeutics ( SGMO ) is a clinical-stage biotech company focusing on the research and development of genomic medicine across 4 distinct technology platforms: gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. Sangamo is best-known for...
Introduction Celyad ( CYAD ) is a clinical-stage biopharmaceutical company, focusing on the development of CAR-T cell therapy for treating cancers. The company has both autologous and allogeneic technological platforms for CAR-T and has 2 international partnerships with Novartis and Horizo...
Introduction Precision BioSciences ( DTIL ) is a genome editing company dedicated to improving life through their proprietary genome editing platform (“ARCUS”), where they are developing product candidates in three high-value areas: allogeneic CAR T immunotherapy, in vivo g...
News, Short Squeeze, Breakout and More Instantly...
Cellectis Romainville Ord Company Name:
CMVLF Stock Symbol:
OTCMKTS Market:
Cellectis Romainville Ord Website:
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...